Serum Cardiac Troponin and Subclinical Cardiac Status in Pediatric Chronic Renal Failure
,
,#,#,¶¶,||||,**
* Department of Cardiology
Division of Nephrology, Department of Medicine
Department of Laboratory Medicine, Children’s Hospital, Boston, Massachusetts
¶ Division of Biostatistics, Dana Farber Cancer Institute, Boston, Massachusetts
|| Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston, South Carolina
# Department of Pediatrics
** Department of Pathology, Harvard Medical School, Boston, Massachusetts
Division of Pediatric Cardiology, Golisano Children’s Hospital at Strong and University of Rochester Medical Center
Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York
¶¶ Division of Nephrology, Vanderbilt Children’s Hospital
|||| Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
 |
ABSTRACT |
|---|
 TOP ABSTRACT METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Background. Patients with uremia often have elevated serum cardiac troponin T (cTnT) even without clinical heart damage. Pediatric patients are ideal for studies of the relationship between uremia and heart disease because they are unlikely to have cardiac risk factors other than uremia.
Objective. To determine the relationship between uremia and cTnT levels.
Design. Echocardiograms and blood chemistry results were obtained from 50 pediatric patients with chronic renal failure and without clinical heart disease. Levels of cTnT were tested for correlation with cardiac dysfunction. In multivariate analysis, biochemical aspects of renal disease and its treatment were tested for correlation with cardiac dysfunction.
Results. Forty-nine patients had cardiovascular abnormalities, including increased left ventricular function and mass, elevated heart rate and blood pressure, and reduced LV afterload. LV contractility was inversely correlated with cTnT level (r = –0.36). Higher cTnT also correlated with higher serum creatine kinase-MB mass, lower serum parathyroid hormone, higher blood urea nitrogen and bicarbonate levels, and the use of diuretics, but not with higher cardiac troponin I. Left ventricular contractility was inversely related to serum creatinine, phosphorus, and the use of ß-blockers.
Conclusions. Elevated cTnT levels are not artifactual, but are genuine indicators of cardiomyocyte damage. Cardiac damage, indicated by either elevated cTnT or low LV contractility, is related to uremia, deranged calcium and phosphorus metabolism, and bicarbonate levels. Serum cTnT and LV contractility identify subclinical cardiac damage that could be treated to hopefully reduce cardiovascular morbidity and mortality in this high-risk population.
Key Words: chronic renal failure • hemodialysis • pediatrics • troponin • cardiomyopathy • myocardial dysfunction • child • uremia • chronic renal insufficiency
Abbreviations: CRF, chronic renal failure • CK-MB, serum creatine kinase-MB mass • cTnT, serum cardiac troponin T • GFR, glomerular filtration rate • CRI, chronic renal insufficiency • LV, left ventricular • BUN, blood urea nitrogen • PTH, parathyroid hormone • cTnI, serum cardiac troponin I
Cardiovascular disease is the leading cause of death in chronic renal failure (CRF) patients on dialysis, as well as a leading cause of morbidity.1 Rates of cardiovascular disease are up to 20 times higher in adult CRF patients than in the general population.2 Clinical and subclinical myocardial ischemia are common among CRF patients, both before and during dialysis.3,4 Earlier detection of cardiovascular abnormalities in these patients might allow earlier interventions to reduce morbidity and mortality.
Studies of cardiac markers in this population have detected low-level elevations of serum creatine kinase, serum creatine kinase-MB mass ([CK-MB]; the cardiomyocyte-specific fraction), CK-MB isoforms, and serum cardiac troponin T (cTnT).5–9 However, either these findings have not been attributed to myocardial injury (because of factors such as lack of assay specificity), or they have been attributed to injury caused by risk factors other than uremia. These risk factors have included advanced age, atherosclerosis, diabetes, human immunodeficiency virus infection, traumatic injury, and the use of alcohol, cigarettes, or drugs. In addition, some of these previous studies used clinical indicators that were not sensitive enough to detect cardiomyocyte health. Thus, it was not possible to determine if serum marker elevations indicated subclinical myocardial injury related to CRF. A pediatric population with CRF provides an ideal group for the study of cardiac status in uremia, because these patients are less likely to have these potentially confounding risk factors.
In this prospective study, we studied pediatric patients with CRF but without overt heart disease or a history of ischemia or heart disease. We tested elevated serum cardiac markers for correlation with sensitive echocardiographic measures of cardiac structure and function. We also investigated whether any detected cardiac injury was related to either uremia or treatments for uremia.
|
METHODS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Subjects
Children, adolescents, and young adults under 30 years old seen at Children’s Hospital, Boston in January and February 1997 for follow-up of CRF were eligible. The patients had had a glomerular filtration rate (GFR) of <70 mL/min/1.73 m2 for at least 6 months, with a defined cause for renal impairment. CRF patients were in 1 of 3 mutually exclusive groups; chronic renal insufficiency (CRI), hemodialysis, or peritoneal dialysis. No patient had diabetes, recognized atherosclerosis, or human immunodeficiency virus infection, and none reported smoking, drinking, or illicit drug use. No patient had congestive heart failure, angina, or clinical ischemia or was being followed by a cardiologist for left ventricular (LV) dysfunction or arrhythmia. The study was approved by the Committee on Clinical Investigation, and all participants or their parents or guardians provided informed consent.
Renal Therapy
All hemodialysis patients were treated with high-efficiency dialysis using polysulfone dialyzers, bicarbonate-based dialysate, and controlled ultrafiltration. Dialyzers were reprocessed with formalin a maximum of 10 times. Dialysis adequacy was assessed monthly with formal urea kinetic modeling and KT/V, a standard index of dialysis efficiency that is calculated by comparing the patient’s predicted and actual clearance of dialyzable solutes. All patients had KT/V 
1.4, which exceeds National Kidney Foundation-Dialysis Outcome Quality Initiative recommendations.10 The peritoneal dialysis patients were all receiving continuous cycling peritoneal dialysis. Concomitant medications for all dialysis patients included calcium carbonate, calcitriol, and water-soluble vitamins including folate.
Echocardiographic Evaluation
All patients underwent a single study echocardiogram. In the hemodialysis patients, echocardiography was performed immediately before hemodialysis. Echocardiograms were interpreted by echocardiographers masked to the patient’s clinical history. The echocardiographic study consisted of a complete 2-dimensional and Doppler evaluation. The combined M-mode echocardiogram, phonocardiogram, and pulse tracings were digitized and analyzed as previously described11 to derive values for systolic performance, preload, afterload, and contractility. Both conventional endocardial and newer midwall indices of LV performance were measured. In the setting of LV hypertrophy, endocardial indices are artifactually elevated relative to midwall indices, and thus may fail to detect clinically important LV dysfunction found by midwall measurements.12–14 However, midwall indices may be less sensitive because of inaccuracy in wall thickness measurement. Echocardiographic results were compared with data from 296 healthy subjects who were studied according to the same protocol.11
Assays
In hemodialysis patients, serum was taken both before and after hemodialysis. In patients on peritoneal dialysis and CRI patients, serum was obtained at any convenient time. No patient had cardiogenic shock or rhabdomyolysis at the time of sampling. All samples were stored at –70°C for <60 days. Cardiac troponin T was measured by enzyme immunoassay (Elecsys Troponin T STAT) on an Elecsys 1010 system (Roche Diagnostics Corp, Indianapolis, IN). A value of 0.01 ng/mL or higher was considered elevated on the basis of our analytical validity testing. Cardiac troponin I was measured by the Opus Plus analyzer (Behring Diagnostics, Westwood, MA) and in a similar serum cardiac troponin I (cTnI) assay by the Stratus II analyzer (Dade International, Miami, FL). A value of 0.05 ng/mL or greater was considered elevated. The chemical markers listed in Table 2 were measured by standard laboratory methods.
|
Statistical Analyses
Characteristics of the hemodialysis patients and the CRF patients were compared with 2-sided Wilcoxon rank-sum tests (for the continuous outcomes) or Fisher exact tests (for dichotomous outcomes), with an
of .05. All echocardiographic variables were expressed as z scores (normal deviates) relative to the age- or body surface area-appropriate distribution in healthy children as previously described.11 We used a step-up regression procedure (keeping values with P < .05 at each step) to examine the relationships between patient characteristics, serum biochemistry, and cardiac function z scores, controlling for other variables such as hypertension and tachycardia. We examined all the exploratory variables listed in Tables 1 through 3 as predictors. For these step-up regression models, partial correlation coefficients were used to quantify the strength of the association between serum biochemistry and cardiac z scores, controlling for other variables in the model, including cardiac variables such as hypertension. These partial correlation coefficients are given in Tables 4 through 6. Because this was an exploratory analysis, we did not adjust for multiple testing. Therefore, although highlighted significant associations appear meaningful, the P values should be interpreted cautiously.
|
|
|
|
|
RESULTS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Patient Population
Of the 50 participants, 20 had CRI; these were all the patients who had clinic visits during the study period (Table 1). Twenty-seven additional patients were on hemodialysis. The remaining 3 were on peritoneal dialysis; their data are not shown in the tables because there were too few to analyze meaningfully. All eligible patients on hemodialysis who were actively followed during that interval were included, except for 1 patient without known cardiovascular risk factors or abnormalities who declined to participate. No patient had clinical evidence of structural cardiovascular abnormalities except those noted with aortic regurgitation, dilated aortic root, or pericardial effusion.
Patients on hemodialysis were significantly older than those with CRI and were more likely to be receiving erythropoietin and ß-adrenergic antagonist therapy (Table 1). They also had higher serum levels of creatinine and cTnT and lower levels of CK and bicarbonate (Table 2).
Serum Chemistry
Serum cTnT was elevated in 21 patients. Three of 20 (15%) CRI patients had cTnT elevations and 18 of 27 (67%) hemodialysis patients had cTnT elevations. Hemodialysis patients were significantly more likely to have cTnT elevations (P 
.0001). The median cTnT level was 0.013 ng/mL (range: 0–0.239 ng/mL) in hemodialysis patients. All hemodialysis patients with elevated predialysis levels of cTnT also had elevated postdialysis levels. There were no isolated postdialysis cTnT elevations. Pre- and postdialysis cTnT levels were closely correlated (Pearson’s r = 0.98, P < .001), as were predialysis and postdialysis serum CK-MB mass values (r = 0.45, P = .019), suggesting that CK-MB and cTnT are poorly dialyzable under the stated conditions.
Serum cTnI measured by the Behring assay was elevated in 6 patients, 11.1% (3 of 27) of patients on hemodialysis and 15% (3 of 20) of patients with CRI. Two of 3 patients on hemodialysis with elevated cTnI also had elevated cTnT. No patient with CRI who had elevated cTnI had elevated cTnT. No patient had elevated cTnI according to the Dade assay.
CK-MB was elevated (>5 ng/mL) in 6 of the 49 patients (12.2%) who agreed to be followed. In patients on hemodialysis, CK-MB was elevated in 14.8% (4/27) before dialysis and 11.1% (3/27) after dialysis, with no clear pattern of increase or decrease between pre- and postdialysis levels. Two of the patients with CK-MB elevation had cTnT elevation as well. No patient with an elevated CK-MB had elevated cTnI.
Echocardiography (Table 3)
Only 1 of the 50 patients had a normal echocardiogram. The echocardiographic findings based on endocardial measurements included hyperdynamic LV systolic performance with increased LV fractional shortening, reduced LV afterload related to increased LV wall thickness, an increased thickness-to-dimension ratio, and increased mass. Heart rate and diastolic blood pressure were significantly elevated as well. Height and weight at the time of echocardiography were significantly reduced for age and sex. Other anatomic findings by echocardiography included pericardial effusion in 9/50 (18%) patients, aortic regurgitation in 7/50 (14%) patients, and a dilated aortic root in 4/50 (8%) patients. No patient had regional wall motion abnormalities. In the CRI group, the means of 4 aspects of LV function were abnormal (mass, end-diastolic dimension, end-diastolic posterior wall thickness, and stress-shortening index). In the hemodialysis group, 5 measures were abnormal (mean LV mass, fractional shortening, end-diastolic posterior wall thickness, thickness-to-dimension ratio, and afterload).
Multivariate Analysis (Tables 4 Through 6)
Lower LV load-independent contractility was significantly correlated with a lower GFR and not receiving dialysis (Table 4). Lower LV preload-dependent contractility was significantly correlated with higher serum cTnT (Table 5). Serum cTnT correlated directly with CK-MB (Table 5). Serum cTnI did not correlate with any other variable.
|
Because cTnT was negatively correlated with cardiac function (LV contractility) in these patients (partial correlation coefficient = –0.36; P = .032), elevated cTnT would appear to be an indicator of cardiomyocyte damage rather than an artifactual finding. We thus grouped patients with reduced contractility and those with elevated cTnT into a myocellular damage group. In this group, cardiac damage was associated with 2 classes of patient characteristics, as well as with 2 other isolated characteristics. The first class was characteristics associated with uremia itself: having kidneys, having CRI rather than hemodialysis, having a low GFR, having high blood urea nitrogen (BUN), having high creatinine, and using more diuretics. The second class was factors related to calcium-phosphorus homeostasis, including lower parathyroid hormone (PTH) and higher phosphorus. Elevated cTnT was also associated with higher serum bicarbonate levels (Table 5) and lower contractility with ß-adrenergic antagonist therapy (Table 6). Patients taking vasodilators were much more likely to suffer pericardial effusion than were patients not taking vasodilators (odds ratio, 13.60; 95% confidence interval 2.55, 72.53; P = .002).
|
DISCUSSION |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Our first question was whether cTnT elevations in patients with uremia were artifacts or indicators of genuine myocardial injury. We found a moderate but statistically significant inverse correlation between preload-dependent LV contractility and cTnT levels, and we interpret this finding to indicate that elevated cTnT is the result of myocardial injury. None of the patients had clinical signs of myocardial injury, and thus we consider the elevated cTnT to indicate subclinical myocellular damage.
We next examined the patients with either impaired LV contractility or elevated cTnT, because both could be considered to be suffering from myocellular injury. In these myocellular-injury patients, we used regression analysis to determine which aspects of uremia or its treatment contributed to the injury. Overall, worsening renal disease (indicated by increased creatinine and decreased GFR) correlated with LV dysfunction. Tables 4 and 5 show that myocardial impairment or injury correlated with 2 classes of risk factors: uremic substances or markers, and derangements in phosphorus and PTH homeostasis. It also correlated with bicarbonate levels. Also, cTnT abnormalities were more common in patients on dialysis than in patients with CRI.
The echocardiographic findings included increased LV mass with an elevated thickness-to-dimension ratio, reduced afterload (wall stress), elevated endocardial function indices with normal midwall indices, and normal preload. In contrast to adults with CRF,15 this pediatric population had wall stress results implying adequate compensatory hypertrophy.
The cardiac status of children and young adults with CRF is characterized by: hyperdynamic endocardial LV systolic performance with normal contractility; reduced LV afterload related to increased LV wall thickness, mass, and thickness-to-dimension ratio; and an augmented hemodynamic status with tachycardia and hypertension. Cardiac sympathetic overactivity is consistent with these findings,11,16,17 which may ultimately lead to depressed LV contractility, resulting in increased cardiac morbidity and mortality. This study demonstrated significantly lower LV contractility in children taking ß-blockers, reflecting the ability of ß-blockers to reduce adrenergic cardiovascular effects.18
Depressed contractility (defined as levels below the 95% confidence interval for healthy children) was not found in this study. However, as contractility was inversely associated with cTnT levels, it is possible that cardiomyocyte damage is a cause of impaired contractility, and that cumulative injury may result in clinically detectable effects over time.
Worsening renal disease (increased creatinine and decreased GFR) correlated with LV dysfunction. In adult patients with CRF, higher rates of cardiac abnormalities are associated with lower delivered dialysis doses,19 and LV function improves after dialysis in children with CRF,17,20 which is found in this study as well. These observations suggest that dialysis improves cardiac status at a clinical level,21 but do not address the question of whether dialysis prevents subclinical damage. We found that cTnT abnormalities were more common in patients on dialysis than in patients with CRI, which could suggest that dialysis itself is associated with subclinical damage, or that worsening renal function in these patients is associated with both hemodialysis and additional cardiac abnormalities. Other studies have supported dialysis-associated cardiomyocyte injury.9 A decrease in CK and cTnT and an improvement in cardiac status after successful renal transplantation22,23 or nephrectomy24 suggests that one or more factors associated with uremia are cardiotoxic.
In all reports, more patients with CRF have detectable serum cTnT than cTnI,25,26 perhaps because there is a lack of mass standardization of cTnI assays and there is heterogeneneity in the cross-reactivities of antibodies to various troponin I forms.27 Our results confirm that serum cTnI is less sensitive to cardiac injury and suggest that measuring low-level cTnT elevations may help predict or allow the early initiation of preventive strategies to hopefully prevent or reduce cardiovascular morbidity and mortality in this population. Before this study, it was unclear whether cTnT elevations represented subclinical cardiac injury, extracardiac expression of cTnT, or cross-reactions of antibodies associated with CRF or subclinical myocardiocyte damage from cardiac risk factors unrelated to CRF. Elevations of cTnT in CRF are not explained by expression of skeletal muscle troponin T, but are correlated with increased cardiac risk.28,29 Among adults with CRF, median levels of cTnT are 0.21 ng/mL in nondiabetics on hemodialysis, 0.39 ng/mL in diabetics on hemodialysis, and 0.06 ng/mL in diabetics with normal creatinine.30,31 In contrast, the median level among our younger patients was 0 ng/mL (maximum, 0.70 ng/mL). This lower value is to be expected, because young patients have fewer nonuremic cardiac risk factors.
Our results furthermore suggest that serum cTnT may be used to detect minor, clinically occult, myocardial injury in this population, allowing for preventive or corrective strategies. Such an approach would be worthwhile because cardiovascular complications remain the most common cause of death in pediatric patients with CRF. In fact, the percentage of deaths from cardiovascular sequelae are as common in children with CRF as adults.32,33 In addition, young adults with childhood-onset CRF have a high prevalence of persistent arteriopathy associated with indicators of microinflammation, hyperparathyroidism, calcium-phosphate overload, and hyperhomocysteinemia, but not traditional atherogenic risk factors.34
Among our patients, low-level elevations of serum cTnT were common, suggesting subclinical cardiomyocyte injury in many patients on dialysis or with CRI. Although dialysis can reduce injury caused by uremic toxins, it may also increase the cardiotoxicity of other factors, such as calcium, phosphorus, PTH, and bicarbonate. Previous studies of cTnT and of other markers have not examined correlations with LV contractility. The specificity of cTnT elevations for detection of active myocardial damage is supported in this study by significant correlations with both CK-MB and LV contractility. In addition to the significant correlation between preload-dependent contractility and serum cTnT, our data also suggested that there may be a weak correlation between load-independent LV contractility and elevated serum cTnT (r = –.29, P = .099; data not shown). In adults with CRF, low-level elevations of cTnT appear to be predictive of subsequent clinically significant cardiovascular morbidity or mortality.29,35
Our data suggest that uremia contributes to heart disease, because patients with CRF who had lower GFR before beginning dialysis had lower contractility, and because higher concentrations of uremic substances, such as serum creatinine and BUN, correlated with lower contractility and cTnT elevations. Other researchers have found a relationship between cTnT and BUN or creatinine. The concentration-dependent cardiodepressant effects of uremic markers have been described in numerous experimental studies.36–38
As our data imply, abnormalities of calcium and phosphorus homeostasis may be risk factors for the active myocardial injury demonstrated by elevations of cTnT, and could affect the morbidity of patients with CRF. Although we have not explored the exact cause of myocardial injury, ischemia can cause myocardial injury and ischemia is a problem in adults with CRF. PTH is an independent factor influencing cardiac function in pediatric CRF.39 Low PTH levels are correlated with LV dilation in adults with CRF,3 just as lower PTH was correlated with elevated cTnT in our study. The experimental induction of acute hypercalcemia in patients with CRF increases serum-ionized calcium, decreases plasma intact PTH, and significantly impairs LV diastolic function compared with healthy controls.40 Lower PTH may be related to lower intracellular calcium concentration, which can occur during dialysis and is a strong correlate of ischemia,41 depressed contractility,42 and adverse outcomes.43 Impaired cardiac function in experimental renal failure is associated with abnormal cardiac energetics and increased susceptibility to ischemic damage.44 Disordered mitochondrial calcium usage may contribute to these derangements, resulting in impaired cytosolic calcium control, disturbed contractile function, and reduced energy reserves. The use of calcium channel antagonists in this study had a significant effect on LV fiber stress, a result that further demonstrates the effect of calcium on cardiac function.45 In this study, we also found an inverse correlation between phosphorus and both LV contractility and blood pressure. Increased phosphorus has been associated with accelerated formation of calcific valves and advanced coronary plaques, LV dilation, hypotension, bradycardia, and myocardial ultrastructural changes.3,18
Our study suggests a direct relationship between serum bicarbonate and cTnT. The value of bicarbonate use in patients with metabolic acidosis has been questioned. Bicarbonate has disadvantages with respect to hemodynamics, LV function, blood lactate, intracellular pH, oxygen delivery and consumption, and clinical outcome.46–48 Bicarbonate may worsen the local injury in patients with active cardiomyocyte injury.
Multiple cardiac risk factors exist in patients with CRF and may act in concert to produce a high incidence of cardiovascular disease.49 Identifying modifiable independent risk factors for subclinical cardiac disease may lead to clinical strategies to reduce heart disease and mortality. Our study suggests that both uremia and its therapy have cardiovascular risks. Even in the absence of diabetes or atherosclerotic disease, patients with CRF had cardiac injury that was related to factors that are potentially modifiable. Measuring cTnT and LV contractility could provide objective standards of cardiovascular status in patients with CRF and of their response to clinical interventions.50, 51
Although other studies of adults have established a relationship between inadequate dialysis (low KT/V) and cardiovascular morbidity and mortality,52 in this study all patients had adequate dialysis as assessed by KT/V and did not have clinically apparent myocardial disease. This suggests that a KT/V of 1.4 may not be sufficient to avoid myocardial injury or to serve as a predictor of cardiovascular morbidity and mortality for younger patients. Children have longer projected lifespans than older hemodialysis patients and are more likely to have time for the subtle abnormalities detected in this study to evolve into clinically apparent disease. Although a KT/V of 1.4 reflects adequate dialysis, it may not be optimal. The findings of this study suggest further investigation of the appropriate outcome measures in assessing dialysis adequacy in children. Adequate control of myocardial injury may become a part of the definition of adequacy of dialysis, along with an adequate dose of dialysis and adequate protein intake.
|
ACKNOWLEDGMENTS |
|---|
This work was supported in part by grants CA68484, CA34183, CA06516, HL69800, and HL48012 from the National Institutes of Health, Bethesda, Maryland, the David B. Perini, Jr, Quality of Life Program, the Parker Family Foundation, and Roche Diagnostics Corporation.
|
FOOTNOTES |
|---|
Received for publication Oct 29, 2001; Accepted Jan 6, 2003.
Address correspondence to Steven E. Lipshultz, MD, Division of Pediatric Cardiology, University of Rochester Medical Center, 601 Elmwood Ave, Box 631, Rochester, NY 14642. E-mail: steve_lipshultz{at}urmc.rochester.edu
|
REFERENCES |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
1. Raine AE, Margreter R, Brunner FP, et al. Report of management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant.1992; 7 :7 –35
2. Amann K, Ritz E. Cardiac structure and function in renal disease. Curr Opin Nephrol Hyperten.1996; 5 :102 –106[CrossRef][Medline]
3. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int.1995; 47 :186 –192[Web of Science][Medline]
4. Singh N, Langer A, Freeman MR, Goldstein MB. Myocardial alterations during hemodialysis: insights from new noninvasive technology. Am J Nephrol.1994; 14 :173 –181[Web of Science][Medline]
5. McLaurin MD, Apple FS, Voss EM, Herzog CA, Sharkey S. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle.
Clin Chem.1997; 43
:976
–982
6. Apple FS, Sharkey SW, Hoeft P, et al. Prognostic value of serum cardiac troponin I and T in chronic dialysis patients: a 1-year outcomes analysis. Am J Kidney Dis.1997; 29 :399 –403[Web of Science][Medline]
7. Robbins MJ, Epstien EM, Shah S. Creatine kinase subform analysis in hemodialysis patients without acute coronary syndromes. Nephron.1997; 76 :296 –299[Web of Science][Medline]
8. Li D, Keffer J, Corry K, Vazquez M, Jialal I. Nonspecific elevation of troponin T levels in patients with chronic renal failure. Clin Biochem.1995; 28 :474 –477[CrossRef][Web of Science][Medline]
9. Frankel WL, Herold DA, Ziegler TW, Fitzgerald RL. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol.1996; 106 :118 –123[Web of Science][Medline]
10. Anonymous. National Kidney Foundation-DOQI clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis.1997; 30 :515 –566
11. Colan SD, Sanders SP, Ingelfinger JR, Harmon W. Left ventricular mechanics and contractile state in children and young adults with end-stage renal disease: effect of dialysis and renal transplantation. J Am Coll Cardiol.1987; 10 :1085 –1094[Abstract]
12. Shimizu G, Zile MR, Blaustein AS, Gaasch WH. Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements.
Circulation.1985; 71
:266
–272
13. Shimizu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH. Left ventricular midwall mechanics in systemic arterial hypertension: myocardial function is depressed in pressure-overloaded hypertrophy.
Circulation.1991; 83
:1676
–1684
14. De Simone G, Devereux RB, Roman MJ, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol.1994; 23 :1444 –1451[Abstract]
15. London GM, Fabiani F, Marchais SJ, et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int.1987; 31 :973 –980[Web of Science][Medline]
16. Johnstone LM, Jones CL, Grigg LE, Wilkinson JL, Walker RG, Powell HR. Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int.1996; 50 :998 –1006[Web of Science][Medline]
17. Rhodes J, Smolens IA, Tejani A, Schiller MS. Effect of hemodialysis on left ventricular contractility in pediatric patients with end-stage renal disease. Southern Med J.1993; 86 :545 –550[CrossRef][Web of Science][Medline]
18. Ritz E, Deppisch R, Stier E, Hansch G. Atherogenesis and cardiac death: are they related to dialysis procedure and biocompatibility? Nephrol Dial Transplant.1994; 9(suppl 2) :165 –172
19. Bloembergen WE. Cardiac disease in chronic uremia: epidemiology. Adv Ren Replace Ther.1997; 4 :185 –193[Medline]
20. O’Regan S, Villemand D, Revillon L, Robitaille P, Ducharme G, Davignon A. Effects of hemodialysis on myocardial function in pediatric patients. Nephron.1980; 25 :214 –218[Web of Science][Medline]
21. Nixon JV, Mitchell JH, McPhaul JJ, Henrich WL. Effects of hemodialysis on left ventricular function. Dissociation of changes in filling volume and in contractile state. J Clin Invest.1983; 71 :377 –384
22. Wu AH, Feng Y, Roper L, Herbert K, Schweizer R. Cardiac troponins T and I before and after renal transplantation.
Clin Chem.1997; 43
:411
–412
23. Parfrey PS, Harnett JD, Foley RN, et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation.1995; 60 :908 –914[Web of Science][Medline]
24. O’Regan S. Cardiovascular abmormalities in pediatric patients with end-renal stage disease. In: Fine RN, Gruskin AB, eds. End-Stage Renal Disease in Children. Philadelphia, PA: WB Saunders; 1984: 359–374
25. Hafner G, Thome-Kromer B, Schaube J, et al. Cardiac troponins in serum in chronic renal failure.
Clin Chem.1994; 40
:1790
–1791
26. Bhayana V, Gougoulias T, Cohoe S, Henderson AR. Discordance between results for serum troponin T and troponin I in renal disease.
Clin Chem.1995; 41
:312
–317
27. Wu AHB, Feng Y-J, Moore R, et al. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I.
Clin Chem.1998; 44
:1198
–1208
28. Haller C, Zehelein J, Remppis A, Muller-Bardorff M, Katus HA. Cardiac troponin T in patients with end-stage renal disease: absence of expression in truncal skeletal muscle.
Clin Chem.1998; 44
:930
–938
29. Roppolo LP, Fitzgerald R, Dillow J, Ziegler T, Rice M, Maisel A. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran’s Hospital: a pilot study.
J Am Coll Cardiol.1999; 34
:448
–454
30. Akagi M, Nagake Y, Ichikawa H, Makino H, Ota Z. Myocardial troponin T levels in patients with diabetic nephropathy. Jpn J Nephrol.1996; 38 :136 –140
31. Akagi M, Nagake Y, Makino H, Shikata K, Ota Z. A comparative study of myocardial troponin T levels in patients undergoing hemodialysis. Jpn J Nephrol.1995; 37 :639 –643
32. Brunner FP, Broyer M, Brynger H. Demography of dialysis and transplantation in children in Europe, 1985. Report from the European dialysis and transplant association registry.
Nephrol Dial Transplant.1988; 3
:235
–243
33. Scharer K, Schmidt KG, Soergel M. Cardiac function and structure in patients with chronic renal failure. Pediatr Nephrol.1999; 13 :951 –965[CrossRef][Web of Science][Medline]
34. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure.
Circulation.2002; 106
:100
–105
35. Wayland D, Baum H, Schatzle G, Scharf J, Neumeirer D. Cardiac troponin T and I in end-stage renal failure.
Clin Chem.2000; 46
:1345
–1350
36. Facchin L, Vescovo G, Levedianos G, et al. Left ventricular morphology and diastolic function in uraemia: echocardiographic evidence of a specific cardiomyopathy.
Br Heart J.1995; 74
:174
–179
37. Weisensee D, Schnaars Y, Schoeppe W, Bereiter-Hahn J, Low-Friedrich I. Potential uremic toxins modulate energy metabolism of cardiac myocytes in vitro. Exp Nephrol.1997; 5 :194 –200[Web of Science][Medline]
38. Weisensee D, Low-Friedrich I, Richie M, Bereiter-Hahn J, Schoeppe W. In vitro approach to "uremic cardiomyopathy." Nephron.1993; 65 :392 –400[Web of Science][Medline]
39. Litwin M, Kawalec W, Latoszynska J, Grenda R, Smirska E. Cardiac systolic and diastolic function in children on hemodialysis and continuous ambulatory peritoneal dialysis. Contrib Nephrol.1994; 106 :114 –118[Medline]
40. Virtanen VK, Saha HHT, Groundstroem KWE, Seppala ES, Pasternack AL. Calcium infusion and left ventricular diastolic function in patients with chronic renal failure. Nephrol Dial Tranplant.1998; 13 :384 –388
41. Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol.1996; 16 :386 –393[Web of Science][Medline]
42. Lang RM, Fellner SK, Neumann A, Bushinsky DA, Borow KM. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med.1988; 108 :524 –529
43. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis.1990; 15 :458 –462[Web of Science][Medline]
44. Raine AE, Seymour AM, Roberts AF, Radda GK, Ledingham JG. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest.1993; 92 :2934 –2940
45. Schluter K-D, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res.1998; 37 :34 –41[CrossRef][Web of Science][Medline]
46. Sirieix D, Delayance S, Paris M, Massonnet-Castel S, Carpentier A, Baron JF. Tris-hydroxymethane and sodium bicarbonate to buffer metabolic acidosis in an isolated heart model. Am J Respir Crit Care Med.1997; 155 :957 –963[Abstract]
47. Marangoni R, Civardi F, Masi F, et al. Lactate versus bicarbonate on-line hemofiltration: a comparative study. Artif Organs.1995; 19 :490 –495[Web of Science][Medline]
48. Wakabayashi Y, Ohwada T, Kikawada R. Haemo-dialysis/-filtration using sodium bicarbonate depresses cardiac function in critically ill patients with acute renal failure. Japanese Circ J.1994; 58 :81 –86
49. Kaysen GA. The microinflammatory state in uremia: causes and consequences.
J Am Soc Nephrol.2001; 12
:1549
–1557
50. Apple FS, Murakami MAM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease.
Circulation.2002; 106
:2941
–2945
51. Freda BJ, Wilson Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency. Review and clinical implications.
J Am Coll Cardiol.2002; 40
:2065
–2071
52. Bloembergen WE, Stannard DC, Port FK, et al. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int.1996; 50 :557 –565[Web of Science][Medline]
PEDIATRICS (ISSN 1098-4275). ©2003 by the American Academy of Pediatrics
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  D. K. Hothi, L. Rees, J. Marek, J. Burton, and C. W. McIntyre Pediatric Myocardial Stunning Underscores the Cardiac Toxicity of Conventional Hemodialysis Treatments Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 790 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Aschner and R. L. Poland Sodium Bicarbonate: Basically Useless Therapy Pediatrics, October 1, 2008; 122(4): 831 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Becker-Cohen, A. Nir, C. Rinat, S. Feinstein, N. Algur, B. Farber, and Y. Frishberg Risk Factors for Cardiovascular Disease in Children and Young Adults after Renal Transplantation Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1284 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Atar, M. E. Korkmaz, I. A. Atar, O. Gulmez, B. Ozin, H. Bozbas, T. Erol, A. Aydinalp, A. Yildirir, M. Yucel, et al. Effects of metoprolol therapy on cardiac troponin-I levels after elective percutaneous coronary interventions Eur. Heart J., March 1, 2006; 27(5): 547 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lipshultz, N. Rifai, V. M. Dalton, D. E. Levy, L. B. Silverman, S. R. Lipsitz, S. D. Colan, B. L. Asselin, R. D. Barr, L. A. Clavell, et al. The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia N. Engl. J. Med., July 8, 2004; 351(2): 145 - 153. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
